Health ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Regulatory Compliance Regulatory Affairs MASH Treatment Investor Impact Fasedienol Phase 3 Trials Regulatory Issues GLP-1 Agonists Nimacimab Prostate Cancer Therapeutic Areas Safety Concerns BioAge Labs, Inc. Azelaprag Investigational Drugs Syntis Bio Lung Cancer Treatments

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

The case centers on claims Vistagen misled the market about fasedienol’s clinical prospects.

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure

aTyr Investors Face Dec. 8 Deadline as Rival Lawsuits Over Failed Sarcoidosis Trial Intensify

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

New aTyr Class Action Expands Investor Window After EFZO-FIT Failure

Law Firms Urge Jasper Therapeutics Investors to Seek Lead‑Plaintiff Role Before Nov. 18 Deadline